BUY NOVOSARM – ANDARINE (S4) (100 MG/ML – 30 ML)
MAIN PRODUCT DESCRIPTION
NovoSARM – Andarine (S4) 100 mg/ml contains andarine, commonly referred to as S4, a selective androgen receptor modulator (SARM). The supplied product information describes andarine as an investigational compound originally developed during research into conditions involving loss of muscle and bone tissue. The source specifically mentions research areas including muscular dystrophy, osteoporosis and benign prostatic enlargement.
Andarine belongs to a group of compounds designed to interact with androgen receptors. Androgen receptors are cellular proteins through which endogenous androgens such as testosterone and dihydrotestosterone produce biological effects. SARMs were investigated because of the possibility of producing tissue-selective androgen-receptor activity.
Product Specifications
Product: NovoSARM – Andarine (S4)
Strength: 100 mg/ml
Pack Size: 30 ml
Active Compound: Andarine
Alternative Name: S4
Pharmacological Group: Selective Androgen Receptor Modulator
Dosage Form: Liquid preparation, according to the product presentation
Route: Not clearly specified in the supplied information
Regulatory Status: Investigational / not supplied as an approved medicine
Manufacturer: Not supplied
Pharmacological Background
Andarine was developed as part of research into selective androgen receptor modulation. The objective behind SARM research has generally been to identify compounds that interact with androgen receptors in a more tissue-selective manner than traditional anabolic-androgenic steroids.
The supplied source states that andarine has affinity for androgen receptors and discusses its activity in skeletal muscle and bone. However, statements suggesting that SARMs exclusively affect skeletal muscle and bone, or eliminate adverse effects associated with conventional anabolic steroids, are broader than the evidence provided in the source and should not be treated as established clinical facts.
Androgen-receptor signalling is involved in numerous physiological processes. Consequently, altering this signalling pharmacologically can potentially affect multiple tissues and endocrine pathways rather than a single target tissue.
Research Background
The supplied information states that andarine was initially researched by GTX Laboratories in connection with potential treatments for conditions associated with muscle wasting, osteoporosis and benign prostatic enlargement.
The source further states that promising findings were observed in animal research and that human research has been conducted to investigate possible effects on skeletal muscle mass, strength and bone density.
These findings must be distinguished from established clinical treatment. Animal or investigational findings do not by themselves establish clinical efficacy or safety in humans. The supplied material does not provide specific human clinical-trial citations, regulatory approvals or an authorised therapeutic indication for this particular product.
Research Areas
The supplied information discusses several proposed biological effects of S4, including:
Interaction with androgen receptors
Possible effects on skeletal muscle
Possible effects on bone tissue
Changes in body composition
Research into lipid metabolism
Potential effects on strength and muscle mass
These are areas of research rather than verified therapeutic outcomes for the supplied product.
The source also contains statements about improved stamina, reduced fatigue, fat oxidation and conversion of stored fat into muscle tissue. The last of these is not an established physiological process and has therefore not been presented as a factual product benefit.
Aromatisation and Hormonal Activity
The supplied material states that andarine does not undergo aromatisation into oestrogens. Although this characteristic is discussed in the source, it should not be interpreted as meaning that S4 is free from hormonal adverse effects.
Selective androgen receptor modulation can still influence the body’s endocrine system. The supplied information does not provide sufficient clinical data to establish a comprehensive safety profile, particularly regarding long-term hormonal effects.
Bioavailability
The source describes the bioavailability of andarine as high and suggests that relatively small quantities may produce significant pharmacological activity. No independently verified pharmacokinetic values or validated human dosing information were supplied with the product data.
Because the product is investigational, precise claims about bioavailability, therapeutic concentration or clinically appropriate dosage should not be added without reliable supporting documentation.
Use in Fitness and Athletics
The supplied source describes andarine as being used by athletes and bodybuilders for “cutting” and “bulking” and contains claims concerning muscle development, strength and fat loss.
These statements should be distinguished from medical indications. Andarine is not presented here as an approved treatment for bodybuilding, athletic performance, weight reduction or muscle enhancement.
Similarly, the source discusses combining S4 with other SARMs. Such combinations have not been presented as recommendations because the supplied information does not establish their safety or therapeutic value.
Safety Considerations
The product information supplied does not provide a comprehensive adverse-reaction section, clinical safety profile or validated long-term safety data.
Because andarine interacts with androgen receptors and may influence endocrine signalling, research use should be approached with appropriate scientific oversight. Claims that S4 has fewer side effects than traditional anabolic steroids should not be treated as a guarantee of safety.
Regulatory Position
The supplied material states that andarine has not been prescribed by practitioners and describes it as an investigational compound. No EU marketing authorisation, national marketing authorisation number, approved indication or official regulatory authorization was supplied.
Accordingly, NovoSARM – Andarine (S4) should not be described as an EU-approved medicine or as a prescription treatment.
Important Research Notice
Andarine (S4) is an investigational SARM. The supplied product information contains research claims relating to muscle, bone and metabolic pathways, but these should not be presented as proven clinical benefits.
The information above is based solely on the supplied product material. It does not establish safety, efficacy, regulatory approval or an appropriate human treatment regimen. It should not be interpreted as medical advice or as instructions for non-prescribed use.
